Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDRH Guidance Priorities Include Lab-Developed Tests, Adverse Event Reporting, Third-Party 510(k) Review

This article was originally published in The Gray Sheet

Executive Summary

FDA's device center issued its annual “A List” and “B List” guidance priorities for fiscal year 2016, spotlighting efforts to address Unique Device Identification direct marking, Medical Device Reporting rules, laboratory-developed tests, 510(k) third-party review, companion diagnostics, and more.

You may also be interested in...



Bone Anchor 510(k) Guidance Gets Update

US FDA has revised and expanded its 1996 guidelines on bone-anchor submissions. The revision discusses clinical and nonclinical testing standards for devices used to fasten tissue to bone, as well as other 510(k) concerns.

FDA Biocompatibility Tips: Multiple Absorbability, Allergenicity Testing Methods To Choose From

An FDA device reviewer and an agency toxicologist talk to The Gray Sheet about key industry considerations for biocompatibility testing, emphasizing a growing focus on testing absorbable implants and testing for allergens in devices.

FDA Meets With Clinical Decision Support Firms To Address Challenging Cases

The agency recently sat down with members of the Clinical Decision Support Coalition who presented mock case studies of regulatory submissions for software supporting drug therapy decisions. The coalition hopes to get feedback on how FDA intends to regulate such software in the coming months.

Related Content

Topics

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel